Terumo BCT Automates Engineered TIL Production with Quantum Flex
Terumo BCT will automate engineered TIL manufacturing on Quantum Flex with TrAMPoline Pharma and the University of Colorado, targeting a manual three-week process with phased validation and measured potency endpoints.
TAG K-7707 · 487 words on the filing

Summary of findings
- TIL manufacturing currently takes about three weeks using manual, bespoke processes.
- Terumo BCT deploys its Quantum Flex Cell Expansion System for automated engineered TIL production with TrAMPoline Pharma and the University of Colorado.
- Validation runs in phases: first automated cell expansion against the existing process, then integration of further workflow steps.
- Endpoints to be evaluated include gene transfer efficiency, viability, phenotype, tumor-specific killing, yield consistency and turnaround time.
- Neither partner has committed to a target manufacturing timeframe; total time reduction must be established experimentally.
Terumo Blood and Cell Technologies has set out to automate the manufacture of genetically engineered tumor-infiltrating leukocytes, deploying its Quantum Flex Cell Expansion System in a partnership with TrAMPoline Pharma and the University of Colorado. The target is a production process that today takes roughly three weeks and depends on extensive manual handling in bespoke, small-scale laboratory workflows.
The move addresses a structural bottleneck in TIL manufacturing. TILs derive from T cells that have infiltrated tumors, and these cells expand far less efficiently than circulating T cells drawn from the bloodstream. Potent doses therefore require vastly greater starting quantities of T cells, which compounds the variability of inconsistent starting materials and conditions.
What does automation change for the pipeline?
"Automation could help bridge the gap between development in the lab and clinical scale by utilizing the same scalable technology for both phases to ultimately preserve product quality along the development pipeline," said Mindy Miller, PhD, head of cell therapy scientific development at Terumo BCT.
Eduardo Davila, PhD, professor of medicine at the University of Colorado and co-founder and CSO at TrAMPoline Pharma, framed the problem in operational terms: "We recognized that a process dependent on extensive manual handling would inevitably limit clinical translation." Davila's research into T cell infiltration forms the basis of TrAMPoline Pharma's TIL program, and the collaboration, in his words, "aims to make engineered TIL manufacturing more reproducible and efficient while preserving the cells' tumor-fighting capabilities."
The teams are focusing on three concrete levers:
- Standardized culture conditions
- Automated feeding
- Fewer manual manipulations
"Our goal is to preserve engineered TIL identity, viability, and antitumor function," Davila said.
Phased validation, measured claims
The automation program proceeds in phases. The first step validates automated cell expansion against the existing process. Additional steps will then be validated and integrated into the workflow one by one.
The partners are deliberately restrained on timelines. "We anticipate a substantial reduction in hands-on labor and expedited TIL expansion. Whether total manufacturing time also decreases — and by how much — must be established experimentally," Davila said. Miller confirmed that a shortened overall timeline "is still being evaluated." Neither partner would name a target timeframe for engineered TIL manufacturing.
On expected gains, Davila was specific about what the program will measure: "We anticipate more consistent yield, fewer manual interventions, and greater manufacturing capacity, with the potential to reduce cost and turnaround time."
Critically for quality teams, potency is on the test plan rather than the assumptions list. "We will evaluate these gains alongside gene transfer efficiency, viability, phenotype, and tumor-specific killing. Improved potency is an outcome to test, rather than assume," Davila said.
Miller kept the scope tight: "Our focus is adapting automation to the particular requirements of engineered TILs." Terumo BCT joins a handful of companies now working to automate TIL production as the field shifts from bench-scale manual craft toward clinical-scale, reproducible manufacturing.
via s.w.org (Original)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
13 articles
Linked filings
- K-2547
- E-9238
- K-2175
- K-1653
- V-7932